David Sarid

Thanks to 400 of patients and family members from all over the country who subscribed to #bladdercancer webinar this evening. Thanks to great colleagues from @tasmc1 including @RoyManoMD @OferYossepowitch, @yasminNatan-Oz, @sarid_david, and @NiritRotem Lehrer

#prostatecancer robotic surgery, MRI- artificial intelligence based RT,targeted twere discussed this at a national patient conference (>700 registrants) in collaboration with "Living with Prostate Cancer" foundation.. Thanks to @sarid_david @yossepowitch_MD ,Dr Yasmin Natan-Oz

#סרטןהערמונית @cancer_org_il @tasmc1

Bladder Cancer Highlights From #ESMO23: Honored to compare and contrast the design and results of the landmark EV302 and CheckMate901 Phase III trials in the first-line setting of advanced #urothelialcarcinoma #bladdercancer @BladderCancerUS | VuMedi vumedi.com/video/bladder-… via @vumedi

Delighted that NHS Scotland has now approved abiraterone for high risk M0 prostate cancer. @NHSEngland @NICEComms its urgently time to re-assess this. Big OS and MFS gains with 2y therapy healthcareimprovementscotland.org/our_work/techn…

It was a pleasure talking at YNET studio with Dr David Sarid (Head of Israeli Group of GU Oncology) about adjuvant therapy for kidney cancer renal.mednet.co.il/2012/07/603772/